Overview

A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

Status:
Completed
Trial end date:
2014-11-17
Target enrollment:
Participant gender:
Summary
The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with schizophrenia.
Phase:
Phase 3
Details
Lead Sponsor:
Sumitomo Dainippon Pharma Co., Ltd.
Treatments:
Lurasidone Hydrochloride